Skip to content

Effects of Cold Atmospheric Plasma (CAP) on Peritoneal Tumor Tissue

Effects of Cold Atmospheric Plasma (CAP) on Peritoneal Tumor Tissue

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06796634
Enrollment
5
Registered
2025-01-28
Start date
2024-08-21
Completion date
2025-04-01
Last updated
2025-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cold Atmospheric Plasma (CAP), J-Plasma, Peritoneal Tumor

Brief summary

There are to date no studies available that have examined the effects of CAP on tumor tissue in patients. The aim of this study is to investigate these effects in patients undergoing surgery for peritoneal metastases. Tumor nodules will be treated with different durations and intensities of CAP before being surgically removed. The resected nodules will be analyzed for tumor vitality.

Interventions

DEVICEJ-plasma

* Surgery and application of CAP: at the start of surgery, an inventory is made of suitable tumor nodules that will be planned for resection. Nodules should have a maximal size of 2-3 mm, since it is unlikely that bigger lesions can be adequately treated with CAP. * Selected tumor nodules will be treated with the J-plasma device at the standard settings (Helium gas flow of 4 l/min, coagulation and cutting intensity at 35). The distance between the tip of the device and the tissue will be approx. 10 mm. Using a timer and footswitch, nodules will be treated at different power settings and durations: * 15 W, 30W, or 45W * 2, 5, or 10 seconds. * The treated nodules will be resected at least 30 minutes after plasma treatment, and the exact timing will be documented. The samples are split in half: one half is fixed in formalin for histology and immune histochemistry, and the other half is immediately processed for live/death staining using flow cytometry.

Sponsors

University Hospital, Ghent
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with peritoneal metastases undergoing surgery (CRS, debulking), irrespective of the origin. Potential cancer types include ovarian cancer, colorectal cancer, and malignant peritoneal mesothelioma * Written informed consent * Age ≥ 18 years.

Design outcomes

Primary

MeasureTime frameDescription
- Histology:1 yearFollowing resection, FFPE sections will be assessed morphologically, particularly for the extent of tumor necrosis using haematoxylin and eosin staining. IHC staining will be performed to investigate mechanisms of autophagia (p62 and LC3B), apoptosis (cleaved caspase 3) and proliferation (ki67). * Extent of tumor necrosis: morphological assessment * Proliferation: Ki67 via MIB1 * Autophagia: p62 or LC3B * Apoptosis: Caspase 3 antibodies

Countries

Belgium

Contacts

Primary ContactWim Ceelen, professor
wim.ceelen@ugent.be+3293326251
Backup ContactSarah Cosyns, doctor
sarah.cosyns@ugent.be+3293321562

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026